{"id":"NCT00665366","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder","officialTitle":"A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Adjunctive Aripiprazole Therapy in the Treatment of Mania in Bipolar I Disorder Patients Treated on Valproate or Lithium and in Need of Further Clinical Improvement","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-06","primaryCompletion":"2011-10","completion":"2011-10","firstPosted":"2008-04-23","resultsPosted":"2013-02-04","lastUpdate":"2013-12-02"},"enrollment":493,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar Disorder Mania"],"interventions":[{"type":"DRUG","name":"Aripiprazole","otherNames":["Abilify","BMS-337039"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Lithium","otherNames":[]},{"type":"DRUG","name":"Valproate","otherNames":[]}],"arms":[{"label":"Placebo + valproate or lithium","type":"PLACEBO_COMPARATOR"},{"label":"Aripiprazole + valproate or lithium","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to determine whether aripiprazole provides additional clinical benefit to patients with Bipolar I disorder when combined with lithium or valproate over 12 weeks.","primaryOutcome":{"measure":"Change From Baseline in Total Score on the Young Mania Rating Scale (YMRS) (LOCF Data Set)","timeFrame":"Baseline to Week 12","effectByArm":[{"arm":"Placebo + Valproate or Lithium","deltaMin":-11.54,"sd":0.78},{"arm":"Aripiprazole + Valproate or Lithium","deltaMin":-13.57,"sd":0.78}],"pValues":[{"comp":"OG000 vs OG001","p":"0.058"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":10},"locations":{"siteCount":73,"countries":["Austria","Czechia","France","Germany","Greece","Hungary","Italy","Poland","Romania","Russia","South Africa","Spain","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":[],"seeAlso":["http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":180},"commonTop":["Akathisia","Insomnia","Depression","Nausea","Headache"]}}